Clinical Trials Search
A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib.
Primary Objective: - To assess the efficacy (progression-free survival [PFS]) of DCC-2618 by independent radiologic review in patients with advanced gastrointestinal stromal tumors (GIST) who have previously received first-line therapy with imatinib. - To assess objective response rate (ORR) by independent radiologic review using modified RECIST (mRECIST) criteria - To assess Overall Survival (OS)
DCC-2618 (Ripretinib); Sunitinib Malate (SU011248)